Compare Pfizer with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

PFIZER vs CIPLA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More


Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More


Current Valuations

P/E (TTM) x 39.0 22.3 174.8% View Chart
P/BV x 6.6 2.4 268.8% View Chart
Dividend Yield % 0.5 0.7 78.9%  


5-Yr Chart
Click to enlarge
High Rs3,840678 566.4%   
Low Rs2,080484 429.9%   
Sales per share (Unadj.) Rs455.0198.2 229.5%  
Earnings per share (Unadj.) Rs93.818.5 506.3%  
Cash flow per share (Unadj.) Rs109.435.0 312.7%  
Dividends per share (Unadj.) Rs22.503.00 750.0%  
Dividend yield (eoy) %0.80.5 147.2%  
Book value per share (Unadj.) Rs658.2186.3 353.3%  
Shares outstanding (eoy) m45.75805.70 5.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.52.9 222.0%   
Avg P/E ratio x31.631.4 100.6%  
P/CF ratio (eoy) x27.116.6 163.0%  
Price / Book Value ratio x4.53.1 144.2%  
Dividend payout %24.016.2 148.1%   
Avg Mkt Cap Rs m135,420468,031 28.9%   
No. of employees `0002.622.6 11.6%   
Total wages/salary Rs m3,23828,565 11.3%   
Avg. sales/employee Rs Th7,911.47,053.1 112.2%   
Avg. wages/employee Rs Th1,230.91,261.5 97.6%   
Avg. net profit/employee Rs Th1,630.7659.1 247.4%   
Net Sales Rs m20,815159,710 13.0%  
Other income Rs m1,6744,766 35.1%   
Total revenues Rs m22,489164,475 13.7%   
Gross profit Rs m5,71230,973 18.4%  
Depreciation Rs m71413,263 5.4%   
Interest Rs m731,684 4.3%   
Profit before tax Rs m6,59920,791 31.7%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,3095,695 40.5%   
Profit after tax Rs m4,29114,924 28.7%  
Gross profit margin %27.419.4 141.5%  
Effective tax rate %35.027.4 127.7%   
Net profit margin %20.69.3 220.6%  
Current assets Rs m27,167124,266 21.9%   
Current liabilities Rs m8,91737,715 23.6%   
Net working cap to sales %87.754.2 161.8%  
Current ratio x3.03.3 92.5%  
Inventory Days Days6891 74.8%  
Debtors Days Days3095 31.7%  
Net fixed assets Rs m8,862105,190 8.4%   
Share capital Rs m4581,611 28.4%   
"Free" reserves Rs m29,656148,511 20.0%   
Net worth Rs m30,113150,123 20.1%   
Long term debt Rs m2538,301 0.1%   
Total assets Rs m39,400239,633 16.4%  
Interest coverage x91.513.3 685.9%   
Debt to equity ratio x00.3 0.3%  
Sales to assets ratio x0.50.7 79.3%   
Return on assets %11.16.9 159.8%  
Return on equity %14.29.9 143.3%  
Return on capital %22.111.8 187.0%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42857,410 0.7%   
Fx outflow Rs m78619,041 4.1%   
Net fx Rs m-35838,368 -0.9%   
From Operations Rs m97816,911 5.8%  
From Investments Rs m351-16,687 -2.1%  
From Financial Activity Rs m-1,099-3,487 31.5%  
Net Cashflow Rs m231-3,451 -6.7%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 63.9 20.8 307.2%  
Indian inst/Mut Fund % 7.5 12.2 61.5%  
FIIs % 4.9 23.7 20.7%  
ADR/GDR % 0.0 1.1 -  
Free float % 23.7 26.2 90.5%  
Shareholders   85,207 161,166 52.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster


Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 0.6% (Market Updates)

Dec 6, 2019 | Updated on Dec 6, 2019

DIVIS LABORATORIES share price has hit an all time high at Rs 1,824 (up 1.0%). The BSE HEALTHCARE Index is up by 0.6%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 1.0%) and PFIZER (up 1.0%). The top losers include AJANTA PHARMA and BLISS GVS PHARMA .

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms


Dec 6, 2019 03:31 PM